141095-78-5

Basic information

• Product Name: Ethanone, 2-bromo-1-(tetrahydro-2H-pyran-4-yl)- (9CI)
• Synonyms: Ethanone, 2-bromo-1-(tetrahydro-2H-pyran-4-yl)- (9CI);2-BroMo-1-(Tetrahydro-pyran-4-yl)-ethanone;2 - BroMo - 1 - (tetrahydro - 2H - pyran - 4 - yl)ethanone;2-bromo-1-(tetrahydro-2H-pyran-4-yl)ethan-1-one;2-bromo-1-(oxan-4-yl)ethan-1-one;EOS-61642
• CAS NO: 141095-78-5
• Molecular Formula: C₇H₁₁BrO₂
• Molecular Weight: 207.06504
• Product Categories: ACETYLHALIDE
• Mol File: 141095-78-5.mol

Chemical Properties

• Melting Point: 50-53 °C
• Boiling Point: 271.1±30.0 °C(Predicted)
• Appearance: /
• Density: 1.458±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Ethanone, 2-bromo-1-(tetrahydro-2H-pyran-4-yl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 2-bromo-1-(tetrahydro-2H-pyran-4-yl)- (9CI)(141095-78-5)
• EPA Substance Registry System: Ethanone, 2-bromo-1-(tetrahydro-2H-pyran-4-yl)- (9CI)(141095-78-5)

Safety Data

• Hazardous Substances Data: 141095-78-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethanone, 2-bromo-1-(tetrahydro-2H-pyran-4-yl)(9CI) is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with improved therapeutic properties and reduced side effects.
Used in Agrochemical Industry:
In the agrochemical industry, Ethanone, 2-bromo-1-(tetrahydro-2H-pyran-4-yl)(9CI) serves as an essential building block for the creation of novel agrochemicals. Its incorporation into these products can lead to enhanced crop protection and increased agricultural productivity.
Used in Fine Chemicals Production:
Ethanone, 2-bromo-1-(tetrahydro-2H-pyran-4-yl)(9CI) is also employed in the production of fine chemicals, which are high-purity chemicals used in various applications such as fragrances, dyes, and specialty chemicals. Its unique properties make it a valuable component in the synthesis of these high-value products.
Safety Considerations:
It is crucial to handle Ethanone, 2-bromo-1-(tetrahydro-2H-pyran-4-yl)(9CI) with caution due to its potential health hazards and safety concerns. Proper safety measures should be implemented in laboratory and industrial settings to minimize risks associated with its use.

Upstream product

• 40191-32-0 tetrahydro-2H-pyran-4-carbonylchloride 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 186581-53-3 diazomethane 
• 137052-08-5 1-(tetrahydro-2H-pyran-4-yl)ethan-1-one 
• 80520-85-0 2-diazo-1-(tetrahydro-2H-pyran-4-yl)ethanone 

Downstream Products

• 1232035-08-3 [3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-[2-(tetrahydropyran-4-yl)-imidazo[1,2-a]pyridin-8-yl]amine 

Relevant articles and documents

Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as novel, potent of ALK5 receptor inhibitors

The transforming growth factor type β receptor I (TGF-β R1, also known as activin-like kinase 5 or ALK5) plays a significant role in the pathogenesis of multiple diseases such as malignant tumors and tissue fibrosis. Specific inhibition of ALK5 provides a novel method for controlling the development of cancers and fibrotic diseases. Herein, a novel series of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives was synthesized and identified as ALK5 inhibitors. Among them, compound 8h inhibited ALK5 autophosphorylation and NIH3T3 cell activity with IC50 values of 25 nM and 74.6 nM, respectively. Compound 8h also showed favorable pharmacokinetic profile and ameliorated hERG inhibition. More importantly, 30 mg/kg oral administration of 8h could significantly induce tumour growth inhibition in CT26 xenograft model without obvious toxicity.

Crystal form of quinoline TGF-beta1 inhibitor

The invention belongs to the field of medical chemistry, and relates to a crystal form of a quinoline TGF-beta1 inhibitor as well as a preparation method and application of the crystal form, in particular to a crystal form of 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-yl) oxy)-7-(3-(trifluoromethyl)-5, 6-dihydro-[1, 2, 4] triazolo [4, 3-a] pyrazine-7 (8H)-yl) quinoline as shown in a formula (I) and a preparation method of the crystal form. The crystal form can be used for preparing medicines for treating and/or preventing cancers, tissue hyperplasia diseases, fibrosis or inflammatory diseases.

Method for preparing quinoline TGF-β1 inhibitor

The invention belongs to the field of pharmaceutical chemistry, and relates to a preparation method of quinoline TGF-β1 inhibitor, in particular to I ((4 -) propyl 1 - (tetrahydro -3 - pyran - 2H - yl) -4 - pyrazole - 1H -yloxy) -4 - (-7 - (trifluoromethyl) 3 -5 dihydro 6 - [- 1] triazolo [2, 4] pyrazine 4 (8H) 3 - a -7-yl) quinoline or a salt thereof. A process for the preparation of a hydrate, solvate or crystal.

Quinoline compound Preparation method and application thereof

The invention belongs to the field of pharmaceutical chemistry, and particularly relates to a quinoline compound, a preparation method thereof and application thereof as reference control product in 4 - ((1 - cyclopropyl -3 - (tetrahydro - 2H - pyran -4 - yl) - 1H - pyrazole -4 -yloxy) -7 - (3 -trifluoromethyl) -5, 6 - dihydro - [1, 2] pyrazino [4, 4] pyrazine 3 - a (8H) -7 -yl) quinoline bulk drug.

Medicinal salt of quinoline TGF-beta1 inhibitor and preparation method thereof

The invention belongs to the field of medical chemistry, and relates to a medicinal salt of a quinoline TGF-beta1 inhibitor, or a hydrate, a solvate or a crystal thereof, and a preparation method and application thereof. Specifically, the invention relates to a medicinal salt of 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-yl) oxy)-7-(3-(trifluoromethyl)-5, 6-dihydro-[1, 2, 4] triazolo [4, 3-a] pyrazine-7 (8H)-yl) quinoline as shown in a formula (I), or a hydrate, a solvate or a crystal thereof, and a preparation method thereof. The medicinal salt or the hydrate, the solvate or the crystal thereof can be used for preparing medicines for treating and/or preventing cancers, tissue hyperplasia diseases, fibrosis or inflammatory diseases.

SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.

SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

2-aryl-4-(4-pyrazoloxy)pyridine compound as well as preparation method, pharmaceutical composition and application thereof

The invention relates to a 2-aryl-4-(4-pyrazoloxy)pyridine compound as well as a preparation method, a pharmaceutical composition and application thereof. The 2-aryl-4-(4-pyrazoloxy) pyridine compoundis specifically a 2-aryl-4-(4-pyrazoloxy)pyridine compound with a structural general formula shown in the specification, or a pharmaceutically acceptable salt thereof. The compound can be used as a therapeutic preparation, especially as a TGF-beta signaling pathway inhibitor, and has a good application prospect in preparation of drugs for preventing, alleviating and treating diseases mediated byTGF-beta signaling pathway disorder.

4-(4-pyrazoloxy)quinoline compound and preparation method thereof, pharmaceutical composition and application for 4-(4-pyrazoloxy)quinoline compound and pharmaceutical composition

The invention relates to a 4-(4-pyrazoloxy)quinoline compound and a preparation method thereof, a pharmaceutical composition and an application for 4-(4-pyrazoloxy)quinoline compound and pharmaceutical composition The invention specifically provides a 4-(4-pyrazoloxy)quinoline compound with a structural general formula as shown in the specification, or a tautomer, a mesomer, a raceme, an enantiomer, a diastereoisomer or a pharmaceutically acceptable salt thereof. The compound provided by the invention can be used as a therapeutic preparation, specifically as a TGF-beta signaling pathway inhibitor, and has good application prospects in preparation of drugs for prevention, mitigation and treatment of TGF-beta signaling pathway disorder mediated diseases.

Compound serving as TGF-betaR1 inhibitor and application of compound

The invention belongs to the field of medical chemistry. The invention relates to a compound serving as a TGF-betaR1 inhibitor and application of the compound. Specifically, the invention provides a compound shown as a formula I or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, the invention also relates to a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds or the composition in treatment and/or prevention of TGF-betaR1 related diseases, such as cancers, tissue hyperplasia diseases, fibrosis and inflammatory diseases. The compound provided by the invention shows significant inhibitory activity on TGF-betaR1 kinase, and is very expected to become a therapeutic agent for TGF-betaR1 related diseases.